| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H20N6O |
| Molecular Weight | 420.4659 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(=N1)C2=C(N=C(CC3=CC(=CC=C3)C(N)=O)N2)C4=CC=C5N=CC=NC5=C4
InChI
InChIKey=RYKSGWSKILPDDY-UHFFFAOYSA-N
InChI=1S/C25H20N6O/c1-15-4-2-7-20(29-15)24-23(17-8-9-19-21(14-17)28-11-10-27-19)30-22(31-24)13-16-5-3-6-18(12-16)25(26)32/h2-12,14H,13H2,1H3,(H2,26,32)(H,30,31)
| Molecular Formula | C25H20N6O |
| Molecular Weight | 420.4659 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
IN-1130 as a potent small molecule inhibitor of TGF-β signaling pathway. IN-1130 is a highly selective small molecule ALK5 inhibitor with >100 fold selectivity over p38α and a panel of 26 other serine/threonine and tyrosine kinases. It is a suppressor of fibrogenic process of unilateral ureteral obstruction in rats underscoring the potential clinical benefits in the treatment of renal fibrosis. IN-1130 may potentially treat prostate cancer and breast cancer (preclinical investigation phase).
Originator
Approval Year
PubMed
Patents
Sample Use Guides
40 mg/kg in 100 ul saline 3 times per week for 3 weeks.
Route of Administration:
Intraperitoneal
